Elevated plasma matrix metalloproteinase-9 protein and its gene polymorphism in patients with community-acquired pneumonia

Ting Yen Chiang, Ling Yuh Shyu, Thomas Chang Yao Tsao, Ming Hsien Chien, Shih Ming Tsao, Yuan Ti Lee, Shun Fa Yang

研究成果: 雜誌貢獻文章

9 引文 斯高帕斯(Scopus)

摘要

Background: The purpose here was to detect the association among plasma matrix metalloproteinase-9 (MMP-9) concentration, single nucleotide polymorphisms (SNPs) of MMP-9 gene and community-acquired pneumonia (CAP). Methods: The enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) were, respectively used to measure the plasma MMP-9 level and its gene polymorphisms. Results: The level of plasma of MMP-9 was elevated in patients with CAP as compared to that of normal controls and decreased significantly after treatment. Plasma MMP-9 concentration was significantly correlated with white blood cell (WBC) and neutrophil counts in patients with CAP. No significant difference was found in the genotypes distribution of MMP-9 SNPs, rs3918242, rs17576 or rs2274756, between patients with CAP and normal controls. Plasma MMP-9 concentration was not associated with MMP-9 polymorphism. When the cut-off level of the plasma MMP-9 concentration was set to be 105.02 ng/mL, the odds ratio of plasma MMP-9 for CAP risk was 9.86 (95 confident interval: 4.2722.75). Plasma MMP-9 level may act as a prediction marker for CAP. Conclusions: Elevated plasma MMP-9 could be a biological marker for the diagnosis and be a new strategy for target therapy of community-acquired pneumonia.

原文英語
頁(從 - 到)449-454
頁數6
期刊Clinical Chemistry and Laboratory Medicine
50
發行號3
DOIs
出版狀態已發佈 - 三月 1 2012

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

指紋 深入研究「Elevated plasma matrix metalloproteinase-9 protein and its gene polymorphism in patients with community-acquired pneumonia」主題。共同形成了獨特的指紋。

  • 引用此